Rhumbline Advisers Marker Therapeutics, Inc. Transaction History

Rhumbline Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$1.88 - $3.56 $47,579 - $90,096	-25,308 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$1.47 - $3.29 $147 - $329	100 Added 0.4%	25,308 $57,000
Q4 2020 Feb 10, 2021	BUY	$1.36 - $1.75 $4,545 - $5,848	3,342 Added 15.28%	25,208 $37,000
Q3 2020 Nov 12, 2020	SELL	$1.5 - $2.2 $13,177 - $19,327	-8,785 Reduced 28.66%	21,866 $33,000
Q2 2020 Aug 13, 2020	BUY	$1.69 - $2.79 $14,407 - $23,784	8,525 Added 38.53%	30,651 $63,000
Q4 2019 Feb 05, 2020	BUY	$2.68 - $4.85 $1,037 - $1,876	387 Added 1.78%	22,126 $64,000
Q3 2019 Oct 23, 2019	BUY	$4.1 - $9.0 $4,341 - $9,531	1,059 Added 5.12%	21,739 $111,000
Q2 2019 Aug 14, 2019	BUY	$5.15 - $7.92 $106,502 - $163,785	20,680 New	20,680 $164,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $135M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.